A highly speculative, high-risk, high-reward investment whose future is almost entirely dependent on a regulatory outcome with the FDA. A positive catalyst could be the FDA reversing its decision on the company's data submission.

Mentioned briefly as a biotech stock the speaker likes and considers a 'long' position.

Described as a 'big win' for the speaker's portfolio, with a continued positive outlook expressed as 'I like Cure. It's gone up a lot.'